Authorization

Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

HATTERSHEIM AM MAIN, Germany, Jan. 24, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 AntitrypsinA  (AAT) therapy and RespreezaA® as standard treatment for slowing the progression of emphysema arising from Alpha 1 Antitrypsin Deficiency (AATD). CSL Behring is now able to provide the therapy to patients in Denmark with immediate effect.
Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients
RespreezaA® is a highly purified alpha-1 protein, derived from human plasma and indicated to treat patients with Alpha 1 Antitrypsin Deficiency (AATD). It is the only Alpha 1 proteinase therapy that in a randomised controlled trial has been proven to be disease-modifying, by significantly reducing the loss of lung tissue, thereby slowing the progression of emphysema due to Alpha 1 Antitrypsin Deficiency.AATD is a hereditary condition marked by a lack of the Alpha 1 Antitrypsin protein, whose main function is to protect the lungs from inflammation. RespreezaA® replaces the protein that these patients are missing and raises the Alpha 1 Antitrypsin levels in their blood, which can help to protect the lungs from damage due to inflammation.The Danish Medicines Council estimates that this decision could benefit up to 80 patients in Denmark who, currently, are eligible for treatment with AAT therapy.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2020    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
27282930